As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.Featuring guests:Bert Bruce, Regional President, North America, Rare Disease, Pfizer Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, PfizerDurhane Wong-Rieger, President & CEO at Canadian Organization for Rare DisordersEmily Crossley, Chief Executive Officer, Duchenne UKErik Paulsen, Chair, Institute for Gene TherapiesKarolina Hanslik, Senior Project Manager, EURORDISKatherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, PfizerNikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, PfizerSuneet Varma, Global President, Rare Disease, PfizerTomislav Sokol, Member of European Parliament